Sai Life Sciences: Building the Next Leg of Growth
FY26 showed what Sai Life Sciences looks like when revenue scales: 29% sales growth, EBITDA up 56% and margins from 25% to 30%. Now it is committing the largest capex programme in its history. This note is open to everyone, free to read in full.
| Metric | Value |
|---|---|
| FY26 revenue +29% YoY | ₹2,192 crore |
| FY26 EBITDA +56% YoY | ₹661 crore |
| FY26 EBITDA margin up from roughly 25% | ~30% |
| FY26 PAT +105%; ₹355 crore before exceptional items | ₹349 crore |
| Q1 FY27 revenue +12% YoY | ₹554 crore |
| Q1 FY27 EBITDA margin 25% a year earlier | ~27% |
| CDMO / CRO mix (FY26) ₹1,417 crore up 33%; ₹775 crore up 24% | 65% / 35% |
| FY27 capex guidance largest in company history; ₹633 crore in FY26 | ₹1,100–1,300 crore |
| Manufacturing capacity ~450 KL being added; ~65% utilised in Q1 FY27 | ~700 KL → ~1,150 KL |
| Exports one customer ~12% of revenue | 96.84% of FY26 turnover |
The core question
FY26 showed what Sai Life Sciences can look like when revenue scales: strong sales growth, sharp margin expansion and significant operating leverage. The next phase is different. The company is now committing its largest capex programme yet. The story from here is about whether that investment converts into higher utilization, faster CDMO growth and another leg of earnings growth without diluting returns on capital.
I started looking at Sai Life Sciences from a fairly simple question: what is the company doing today that can make revenue and earnings materially bigger over the next few years? Once the pharma terminology is stripped away, that is really what matters.
Sai works with global pharmaceutical and biotech companies across the drug-development journey. It can enter at the discovery stage, stay involved through process development and clinical manufacturing, and, if the molecule progresses far enough, manufacture it commercially. The attraction of the model is not just winning more projects. It is getting involved earlier, doing more work for the same customer and staying with a molecule for longer.
Understanding the business without the jargon
Suppose a pharma company is working on a new molecule. At the beginning, it needs scientists to design, synthesise and test possible compounds. Sai can provide medicinal chemistry, biology, DMPK and other scientific capabilities. This is broadly the discovery or CRO side of the business.
If the molecule looks promising, the problem changes. The customer now has to figure out how to manufacture it reliably. A reaction that works in a laboratory may not work when the batch size increases sharply. Impurities have to be controlled, yields need to improve and the process must become reproducible. Sai can help with process development, analytical work and the manufacture of material required for clinical trials.
If the drug eventually reaches the market, Sai can potentially continue manufacturing the active ingredient or intermediates at commercial scale. That is the CMC/CDMO side of the business. The economic opportunity generally becomes larger as the molecule moves deeper into development and commercial supply.
This also means Sai does not need every molecule to become a blockbuster before it earns money. It is paid for research, development and manufacturing work along the way. But a molecule that keeps progressing gives Sai the chance to earn more work over a much longer period.
In FY26, CDMO contributed about 65% of revenue and CRO about 35%. CDMO revenue was ₹1,417 crore, up 33%, while CRO revenue was ₹775 crore, up 24%. The two businesses also have different customer mixes. Discovery (CRO) was roughly 48% pharma and 52% biotech in FY26, while CDMO was about 94% pharma and 6% biotech.
The more interesting part is what happens after the first project
Sai is not only trying to keep adding unrelated customers. It is trying to increase the amount of work it does for customers it already knows. That is important because in this industry trust, scientific knowledge, process history, execution and regulatory comfort accumulate over time.
The contribution from Sai's 19 large global pharma customers increased from 28% of revenue in FY22 to 49% in FY26. More than 65% of discovery programmes were integrated, meaning customers were using multiple capabilities rather than one isolated service. Returning customers accounted for more than 90% of revenue in FY25 and FY26.
That does not make customers captive. They can move work elsewhere. But every year spent working on a customer's chemistry, process and development programme creates knowledge that is not instantly recreated at another supplier. In a regulated industry, consistent execution itself becomes valuable.
This is where the dedicated FTE model becomes particularly interesting. Instead of waiting for a customer to send a one-off project, Sai can have dedicated scientific teams working with the customer for longer periods. If those relationships broaden, Sai gets a better chance of participating in later stages of the molecule's life.
By Q1 FY27, Sai reported 33 active commercial molecules and 14 late-phase molecules. Management said six late-phase molecules had entered the pipeline over the preceding 15 months and five of those came from large-pharma customers where Sai already had FTE engagements. One relationship had expanded from a smaller engagement into an end-to-end collaboration spanning discovery to late-stage manufacturing.
That is the model I would want to see repeat: a small relationship becomes a larger one, a discovery programme becomes development work, late-stage assets enter the pipeline and a portion of those eventually become commercial manufacturing opportunities.
The sector backdrop is supportive, but the cycle still matters
There are a few structural themes working in the background. Management says global pharma companies are increasingly outsourcing more of the drug-development lifecycle and are also diversifying supply chains geographically. The company's own annual report describes large pharma as increasingly consolidating discovery, development and manufacturing relationships with strategic partners, with India becoming more relevant in that shift.
Sai is already overwhelmingly exposed to global demand. Exports accounted for 96.84% of FY26 turnover.
The macro sensitivity is not identical across the business. Discovery still has meaningful biotech exposure, and biotech funding conditions can influence how aggressively smaller companies spend on research programmes. CDMO is much more weighted to established pharma customers, where the demand driver is more about development progress, commercial volumes and supply-chain decisions.
There are also near-term macro headwinds. Management has said Middle East tensions have increased input and logistics costs. It has entered customer discussions for price revisions, but those recoveries may not happen in the same quarter as the cost increase. The company has also been monitoring the tariff environment, while saying it had not seen a meaningful impact at the time of the FY26 presentation.
FY26 showed what the model can do when revenue scales
The FY26 numbers were strong. Revenue from operations increased to ₹2,192 crore, up 29%. EBITDA rose to ₹661 crore, up 56%, and EBITDA margin expanded from roughly 25% to 30%. Reported PAT was ₹349 crore, up 105%; the company's investor presentation shows ₹355 crore before exceptional items.
The important part is not simply that sales grew. EBITDA grew much faster than sales. That is operating leverage. The company attributed FY26 margin expansion to better absorption of employee costs, improved material margins and lower other expenses relative to revenue.
The quarterly numbers tell a more nuanced story
| Metric | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 496 | 537 | 556 | 602 | 554 |
| Revenue growth YoY | 77% | 36% | 27% | ~4% | 12% |
| EBITDA (₹ cr) | 125 | 156 | 191 | 189 | 148 |
| EBITDA growth YoY | 305% | 43% | 54% | ~17% | 18% |
| EBITDA margin | 25% | 29% | 34.4% | 31% | 27% |
| PAT (₹ cr) | 60 | 84 | 100 | 104 | 73 |
The pace of sales growth clearly slowed through FY26. Revenue growth moved from 77% in Q1 to 36% in Q2, 27% in Q3 and roughly 4% in Q4. Q1 FY27 improved to 12%, but that is still far below the exceptional growth seen at the start of FY26.
The Q1 FY26 number also needs context. CDMO revenue grew 113% that quarter, while CRO grew 38%. That was an unusually strong base and was never a sensible run rate to extrapolate.
What is more useful is to understand where the slowdown came from. Based on the company's nine-month and full-year disclosures, Q4 FY26 CDMO revenue works out to roughly ₹389 crore versus about ₹405 crore in Q4 FY25, a decline of around 4%. CRO, by contrast, works out to roughly ₹213 crore versus ₹174 crore, growth of about 22%. In other words, the Q4 slowdown was largely a CDMO issue rather than a collapse in discovery demand.
Q1 FY27 broadly continued that split. Total revenue grew 12%, while the investor presentation reported discovery (CRO) growth of 24% — hence discovery remained much stronger than CDMO in the quarter.
Operating leverage is still the part I find most important
Through FY26, EBITDA margin moved from 25% in Q1 to 29% in Q2 and 34.4% in Q3.
Margins then normalized to 31% in Q4 and around 27% in Q1 FY27. I would therefore be careful about treating the Q3 peak as a permanent run rate. The more relevant comparison is that Q1 FY27 margin was still above the 25% reported a year earlier.
The structure of Q1 FY27 was still healthy. Revenue grew 12%, EBITDA grew 18% and PAT grew 22%. Earnings continued to grow faster than sales. That tells me operating leverage has not disappeared; it has simply become much less dramatic than it was during the strongest part of FY26.
PAT growth had another tailwind: lower finance costs
Sai's earnings improvement was not only operational. The company used ₹720 crore of IPO proceeds to repay borrowings. Finance costs fell sharply in FY26, which gave PAT an additional boost below EBITDA.
That distinction matters for the next phase. The deleveraging benefit has largely happened. From here, PAT growth will need to depend more on the core business: sales growth, utilization, margins and the returns earned on the new capacity being added.
The real story from here is the capex cycle
Sai spent around ₹633 crore on capex in FY26. For FY27, management has guided to ₹1,100-1,300 crore, the largest annual investment programme in the company's history. The majority is directed towards capacity expansion, with the balance going towards capabilities, automation, AI and newer technologies.
Manufacturing capacity had reached roughly 700 KL after another ~91 KL was commissioned in Q1 FY26. Sai is now adding roughly 450 KL of further capacity. One ~225 KL production block was targeted around Q2 FY27 and the second by the end of FY27. Management subsequently confirmed that the company remains on track to reach about 1,150 KL of manufacturing capacity.
If that happens, the current investment cycle can create another leg of growth. If demand arrives more slowly than capacity, the same capex creates additional depreciation and fixed costs before the revenue arrives. The investment therefore has to be judged by utilization and returns, not by the size of the capex announcement.
The pipeline gives a reason for the capex, but it still has to convert
At FY26-end, Sai reported 34 commercial molecules and 11 Phase III/pre-registration molecules, alongside a much larger early-stage pipeline. It added four commercial molecules during FY26 and management expected at least three of those to contribute meaningfully in FY27.
By Q1 FY27, the commercial count was 33 and the late-phase count had increased to 14.
There are some encouraging signs. Q1 FY27 disclosures said production had commenced for three of the four molecules added to the pipeline in the prior year. Management also described more than 90% pipeline visibility on FY27 targets. Those statements make the H2 execution particularly important.
Management has given us a fairly clear test
Management continues to guide for 15-20% longer-term revenue growth and an EBITDA margin range of 28-30%. It has also said FY27 should be more second-half weighted, with additional capacity expected to come on stream around the end of Q2 or early Q3.
That is useful because we do not have to invent the near-term expectation. Management has already told us what it expects to happen. Q1 FY27 revenue growth was 12%. If H2 is genuinely stronger, the numbers should begin showing some reacceleration as the year progresses.
If they do not, then the questions become very specific: was commissioning delayed, did customer orders move out, did utilization ramp more slowly than expected, or did demand itself weaken? This is the kind of follow-up that matters much more than management saying the long-term opportunity remains large.
What can go wrong with the story
CDMO revenue is not perfectly smooth. Commercial volumes can change, customers can destock, clinical programmes can be delayed and shipments can move between quarters. Molecules can also fail. This is why management repeatedly asks investors to look at the business over a longer period rather than extrapolating one quarter.
That is reasonable, but "lumpiness" should not become a blanket explanation for a sustained deterioration. One weak quarter may mean very little. Several quarters of weak CDMO growth, falling utilization and margin pressure would mean something different.
Customer concentration also needs to be watched. In FY26, one customer contributed more than 10% of group revenue; the disclosed revenue from that customer was about ₹267 crore, or roughly 12% of total revenue. Large customer relationships are valuable, but they can also make individual programme or ordering decisions more visible in reported growth.
Finally, the business is highly export-oriented, so currency, global trade policy, logistics and geopolitical disruption matter. These are not necessarily thesis-breaking risks, but they can create quarterly noise in both revenue and margins.
Where the story stands now
Sai has already shown what the business can look like when utilization improves. FY26 delivered strong sales growth, sharp margin expansion and very strong earnings growth. At the same time, the pace of sales growth slowed considerably by the end of the year, especially in CDMO.
Now the company is making the largest investment in its history. It is expanding manufacturing capacity, adding R&D infrastructure and building capabilities in areas such as peptides, ADCs and advanced process technologies. It is also trying to move deeper into large-pharma relationships so that more work stays with Sai across the life of a molecule.
That makes FY27 an execution year. The thesis is no longer simply that outsourcing to India is a good theme. The company has already put real capital behind that theme. The numbers now need to show that the capacity and customer relationships can produce another leg of growth.
What I would track from here
- Sales growth and its pace. Q1 FY27 was 12% YoY; the key question is whether growth accelerates as management's stronger-H2 thesis begins to play out.
- CDMO growth. Discovery is currently the stronger engine, but CDMO is the larger business and the main beneficiary of the manufacturing expansion.
- EBITDA margin and operating leverage. Management's medium-term range is 28-30%; I would watch whether margins move back into that band as new capacity is utilized.
- PAT growth quality. With much of the deleveraging benefit already captured, future PAT growth should increasingly come from the operating business rather than lower interest expense.
- Capacity commissioning and utilization. The move towards roughly 1,150 KL matters only if new blocks start on time and utilization rises from the roughly 65% reported in Q1 FY27.
- Late-phase to commercial conversion. I would focus less on the headline molecule count and more on how many late-stage programmes actually become commercial revenue contributors.
- Large-pharma relationship depth. The FTE model becomes more valuable if it consistently feeds process-development, late-stage and commercial work.
- Cash flow and ROCE. The ₹1,100-1,300 crore FY27 capex programme is a major capital-allocation decision; the return generated on that capital is as important as the revenue growth it creates.
- Management's H2 commentary. The company has explicitly said the second half should be stronger as capacity comes on stream. That is the cleanest near-term claim to test against the next few quarters.
12 min read